Publications by authors named "Philip DeSimone"

Claim this Profile
N
Neoadjuvant -paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX.
Shawn L Peterson, Muhammad Husnain, Terri Pollack, Agustin Pimentel, Arturo Loaiza-Bonilla, Philip Desimone

Anticancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.
Talal Hilal, Mary Nakazawa, Jacob Hodskins, John L Villano, Aju Mathew, Philip DeSimone

BMC Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.
Hayder Saeed, Dima Hnoosh, Bin Huang, Eric B Durbin, Patrick C McGrath, Philip Desimone

J Surg Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer recurrence worry, risk perception, and informational-coping styles among Appalachian cancer survivors.
Kimberly M Kelly, Randi Shedlosky-Shoemaker, Kyle Porter, Philip Desimone, Michael Andrykowski

J Psychosoc Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.
Susanne M Arnold, John J Rinehart, Eleftheria Tsakalozou, John R Eckardt, Scott Z Fields, Philip A DeSimone

Clin Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.
Ramesh K Ramanathan, Georg A Bjarnason, Stephen Alan Bernard, Philip Desimone, Theodore Braich

Clin Colorectal Cancer· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer family history reporting: impact of method and psychosocial factors.
Kimberly M Kelly, Randi Shedlosky-Shoemaker, Kyle Porter, Amber Remy, Philip DeSimone

J Genet Couns· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.
Christy M Sapp, Philip DeSimone

Clin Colorectal Cancer· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalation study of ICA-17043 in patients with sickle cell disease.
Kenneth I Ataga, Eugene P Orringer, Lori Styles, Elliott P Vichinsky, Paul Swerdlow, Philip A Desimone

Pharmacotherapy· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm.
Susanne M Arnold, William F Regine, Mansoor M Ahmed, Joseph Valentino, Paul Spring, Philip Desimone

Int J Radiat Oncol Biol Phys· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable local responses with subtherapeutic doses of concurrent radiation and gemcitabine in a patient with refractory Hodgkin's disease.
Maqbool Halepota, Mohammed Mohiuddin, Philip Desimone, Mansoor M Ahmed

Clin Adv Hematol Oncol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis